细胞淋巴瘤-话题@MedSci

#细胞淋巴瘤#

385篇内容 | 5194人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1702723, encodeId=c2411e02723dd, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Lancet Oncol：Zanubrutinib vs 苯达莫司汀-利妥昔单抗治疗初治慢性淋巴细胞白血病和小淋巴细胞淋巴瘤, objectType=article, longId=731945, objectId=fdbde3194517, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdbde3194517, replyNumber=0, likeNumber=74, createdTime=2023-03-06, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdbde3194517, moduleTitle=Lancet Oncol：Zanubrutinib vs 苯达莫司汀-利妥昔单抗治疗初治慢性淋巴细胞白血病和小淋巴细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fdbde3194517)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702719, encodeId=42791e0271945, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=JAMA Oncol：DDGP方案 vs SMILE方案治疗新诊断的局部晚期结外自然杀伤/T细胞淋巴瘤, objectType=article, longId=730250, objectId=b725e302503d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b725e302503d, replyNumber=0, likeNumber=70, createdTime=2023-01-22, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b725e302503d, moduleTitle=JAMA Oncol：DDGP方案 vs SMILE方案治疗新诊断的局部晚期结外自然杀伤/T细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b725e302503d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702692, encodeId=5f991e02692bf, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=百济神州宣布，百悦泽®（泽布替尼）获准用于治疗套细胞淋巴瘤患者, objectType=article, longId=218520, objectId=1ee121852044, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ee121852044, replyNumber=0, likeNumber=90, createdTime=2022-03-01, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ee121852044, moduleTitle=百济神州宣布，百悦泽®（泽布替尼）获准用于治疗套细胞淋巴瘤患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ee121852044)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702715, encodeId=5bbb1e027157e, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=2022 ASCO：戈利昔替尼用于治疗难治性或复发性外周T细胞淋巴瘤的I期/II期研究, objectType=article, longId=728521, objectId=9843e28521fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9843e28521fc, replyNumber=0, likeNumber=72, createdTime=2023-03-10, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9843e28521fc, moduleTitle=2022 ASCO：戈利昔替尼用于治疗难治性或复发性外周T细胞淋巴瘤的I期/II期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9843e28521fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702706, encodeId=32361e02706d5, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=NEJM：侵袭性B细胞淋巴瘤的Tisagenlecleucel或标准治疗比较, objectType=article, longId=298991, objectId=961f298991d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=961f298991d8, replyNumber=0, likeNumber=61, createdTime=2022-11-04, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=961f298991d8, moduleTitle=NEJM：侵袭性B细胞淋巴瘤的Tisagenlecleucel或标准治疗比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=961f298991d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702693, encodeId=92261e02693f5, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Front Oncol：西达本胺（chidamide）治疗中国复发或难治性(R/R) 外周T细胞淋巴瘤（PTCL）的真实世界的疗效, objectType=article, longId=219960, objectId=f2d521996079, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f2d521996079, replyNumber=0, likeNumber=59, createdTime=2021-11-18, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f2d521996079, moduleTitle=Front Oncol：西达本胺（chidamide）治疗中国复发或难治性(R/R) 外周T细胞淋巴瘤（PTCL）的真实世界的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f2d521996079)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702696, encodeId=523b1e02696f0, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=J Clin Oncol：依鲁替尼联合利妥昔单抗一线治疗套细胞淋巴瘤老年患者的疗效, objectType=article, longId=221135, objectId=393f22113570, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=393f22113570, replyNumber=0, likeNumber=90, createdTime=2022-09-03, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=393f22113570, moduleTitle=J Clin Oncol：依鲁替尼联合利妥昔单抗一线治疗套细胞淋巴瘤老年患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=393f22113570)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702713, encodeId=40821e02713d7, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=通用型CAR-NK用于复发/难治性B细胞淋巴瘤，3/6例获得CR, objectType=article, longId=725533, objectId=55e3e255332a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55e3e255332a, replyNumber=0, likeNumber=71, createdTime=2022-07-29, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55e3e255332a, moduleTitle=通用型CAR-NK用于复发/难治性B细胞淋巴瘤，3/6例获得CR, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55e3e255332a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702712, encodeId=ebd11e02712df, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Leukemia：Guadecitabine在外周T细胞淋巴瘤患者中的疗效和安全性, objectType=article, longId=724945, objectId=a43ee2494583, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a43ee2494583, replyNumber=0, likeNumber=75, createdTime=2022-09-05, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a43ee2494583, moduleTitle=Leukemia：Guadecitabine在外周T细胞淋巴瘤患者中的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a43ee2494583)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702708, encodeId=daa31e0270874, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=HAEMATOLOGICA：利妥昔单抗联合基于 LMB 的化疗方案治疗儿童和青少年原发性纵隔大 B 细胞淋巴瘤取得出色的生存率 , objectType=article, longId=300877, objectId=34583008e7c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34583008e7c5, replyNumber=0, likeNumber=96, createdTime=2022-10-14, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34583008e7c5, moduleTitle=HAEMATOLOGICA：利妥昔单抗联合基于 LMB 的化疗方案治疗儿童和青少年原发性纵隔大 B 细胞淋巴瘤取得出色的生存率 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34583008e7c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702686, encodeId=f4a71e0268678, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Blood：结外自然杀伤/T细胞淋巴瘤的新预后预测评分系统！, objectType=article, longId=216362, objectId=99a32163627b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99a32163627b, replyNumber=0, likeNumber=67, createdTime=2021-11-08, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99a32163627b, moduleTitle=Blood：结外自然杀伤/T细胞淋巴瘤的新预后预测评分系统！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=99a32163627b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702674, encodeId=31431e0267479, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Br J Cancer：弥散性大B细胞淋巴瘤DLBCL的新型风险分层预测模型, objectType=article, longId=211832, objectId=fc31211832f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc31211832f6, replyNumber=0, likeNumber=69, createdTime=2021-10-26, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc31211832f6, moduleTitle=Br J Cancer：弥散性大B细胞淋巴瘤DLBCL的新型风险分层预测模型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc31211832f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702677, encodeId=9c281e02677d6, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Blood：糖皮质激素对CAR-T细胞疗法治疗的大B细胞淋巴瘤患者预后的影响, objectType=article, longId=212729, objectId=d16b212e29ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d16b212e29ab, replyNumber=0, likeNumber=87, createdTime=2021-09-15, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d16b212e29ab, moduleTitle=Blood：糖皮质激素对CAR-T细胞疗法治疗的大B细胞淋巴瘤患者预后的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d16b212e29ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702675, encodeId=4d641e02675e6, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Int J Clin Oncol：商品化 CAR T细胞治疗复发/难治性侵袭性B细胞淋巴瘤的疗效, objectType=article, longId=212401, objectId=f48f21240133, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f48f21240133, replyNumber=0, likeNumber=76, createdTime=2021-12-24, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f48f21240133, moduleTitle=Int J Clin Oncol：商品化 CAR T细胞治疗复发/难治性侵袭性B细胞淋巴瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f48f21240133)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702689, encodeId=285c1e0268935, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=J Clin Oncol：DA-EPOCH-R方案治疗原发性纵隔大B细胞淋巴瘤儿童和青少年患者的预后, objectType=article, longId=217929, objectId=39e621e9297d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39e621e9297d, replyNumber=0, likeNumber=84, createdTime=2022-09-10, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39e621e9297d, moduleTitle=J Clin Oncol：DA-EPOCH-R方案治疗原发性纵隔大B细胞淋巴瘤儿童和青少年患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39e621e9297d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702710, encodeId=cc151e02710a3, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Nat Med：Axicabtagene ciloleucel作为高危大B细胞淋巴瘤的一线治疗, objectType=article, longId=301401, objectId=a420301401e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a420301401e0, replyNumber=0, likeNumber=61, createdTime=2022-11-08, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a420301401e0, moduleTitle=Nat Med：Axicabtagene ciloleucel作为高危大B细胞淋巴瘤的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a420301401e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702709, encodeId=ea581e0270900, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Blood：泽布替尼治疗复发/难治性套细胞淋巴瘤的长期疗效, objectType=article, longId=301380, objectId=19cc301380e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19cc301380e9, replyNumber=0, likeNumber=75, createdTime=2023-01-31, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19cc301380e9, moduleTitle=Blood：泽布替尼治疗复发/难治性套细胞淋巴瘤的长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19cc301380e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702687, encodeId=05581e02687fc, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Lancet Oncol：Tisagenlecleucel用于难治/复发性侵袭性B细胞淋巴瘤的长期临床预后, objectType=article, longId=217065, objectId=6c6c21e06592, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c6c21e06592, replyNumber=0, likeNumber=65, createdTime=2022-08-13, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c6c21e06592, moduleTitle=Lancet Oncol：Tisagenlecleucel用于难治/复发性侵袭性B细胞淋巴瘤的长期临床预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c6c21e06592)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702684, encodeId=ae6a1e0268468, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Blood：血管免疫母细胞性T细胞淋巴瘤的预后和预后因素, objectType=article, longId=215164, objectId=2d38215164c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d38215164c7, replyNumber=0, likeNumber=80, createdTime=2021-12-09, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d38215164c7, moduleTitle=Blood：血管免疫母细胞性T细胞淋巴瘤的预后和预后因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d38215164c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702700, encodeId=db291e02700f4, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=STTT：国内多中心研究ORIENT-4证实PD-1抑制剂sintilimab（信迪利单抗）对有复发/难治性结外NK/T细胞淋巴瘤（r/r ENKTL）患者有效且耐受性良好, objectType=article, longId=293110, objectId=00a32931103c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00a32931103c, replyNumber=0, likeNumber=73, createdTime=2022-11-19, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00a32931103c, moduleTitle=STTT：国内多中心研究ORIENT-4证实PD-1抑制剂sintilimab（信迪利单抗）对有复发/难治性结外NK/T细胞淋巴瘤（r/r ENKTL）患者有效且耐受性良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00a32931103c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

细胞淋巴瘤

2020-05-29

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Lancet Oncol：Zanubrutinib vs 苯达莫司汀-利妥昔单抗治疗初治慢性淋巴细胞白血病和小淋巴细胞淋巴瘤

2023-03-06

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

JAMA Oncol：DDGP方案 vs SMILE方案治疗新诊断的局部晚期结外自然杀伤/T细胞淋巴瘤

2023-01-22

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

百济神州宣布，百悦泽®（泽布替尼）获准用于治疗套细胞淋巴瘤患者

2022-03-01

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

2022 ASCO：戈利昔替尼用于治疗难治性或复发性外周T细胞淋巴瘤的I期/II期研究

2023-03-10

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

NEJM：侵袭性B细胞淋巴瘤的Tisagenlecleucel或标准治疗比较

2022-11-04

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Front Oncol：西达本胺（chidamide）治疗中国复发或难治性(R/R) 外周T细胞淋巴瘤（PTCL）的真实世界的疗效

2021-11-18

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

J Clin Oncol：依鲁替尼联合利妥昔单抗一线治疗套细胞淋巴瘤老年患者的疗效

2022-09-03

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

通用型CAR-NK用于复发/难治性B细胞淋巴瘤，3/6例获得CR

2022-07-29

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Leukemia：Guadecitabine在外周T细胞淋巴瘤患者中的疗效和安全性

2022-09-05

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

HAEMATOLOGICA：利妥昔单抗联合基于 LMB 的化疗方案治疗儿童和青少年原发性纵隔大 B 细胞淋巴瘤取得出色的生存率

2022-10-14

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Blood：结外自然杀伤/T细胞淋巴瘤的新预后预测评分系统！

2021-11-08

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Br J Cancer：弥散性大B细胞淋巴瘤DLBCL的新型风险分层预测模型

2021-10-26

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Blood：糖皮质激素对CAR-T细胞疗法治疗的大B细胞淋巴瘤患者预后的影响

2021-09-15

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Int J Clin Oncol：商品化 CAR T细胞治疗复发/难治性侵袭性B细胞淋巴瘤的疗效

2021-12-24

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

J Clin Oncol：DA-EPOCH-R方案治疗原发性纵隔大B细胞淋巴瘤儿童和青少年患者的预后

2022-09-10

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Nat Med：Axicabtagene ciloleucel作为高危大B细胞淋巴瘤的一线治疗

2022-11-08

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Blood：泽布替尼治疗复发/难治性套细胞淋巴瘤的长期疗效

2023-01-31

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Lancet Oncol：Tisagenlecleucel用于难治/复发性侵袭性B细胞淋巴瘤的长期临床预后

2022-08-13

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Blood：血管免疫母细胞性T细胞淋巴瘤的预后和预后因素

2021-12-09

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

STTT：国内多中心研究ORIENT-4证实PD-1抑制剂sintilimab（信迪利单抗）对有复发/难治性结外NK/T细胞淋巴瘤（r/r ENKTL）患者有效且耐受性良好

2022-11-19

科室
- - 订阅+
  - 更多科室
工具
服务